echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Clin Trans Gastroenterology: Risk Factors of Bile Inhalation and Its Impact on Clinical Outcomes

    Clin Trans Gastroenterology: Risk Factors of Bile Inhalation and Its Impact on Clinical Outcomes

    • Last Update: 2021-12-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The symptoms of extraesophageal reflux disease include pharyngitis, chest pain, cough, asthma, aspiration pneumonia, etc.
    , and its diagnosis is difficult because the gold standard test for diagnosing gastroesophageal reflux only measures the load of esophageal reflux, not reflux events.
    The impact of the lungs
    .


    Current studies trying to correlate esophageal reflux exposure with respiratory symptoms have shown conflicting results.


    The symptoms of extraesophageal reflux disease include pharyngitis, chest pain, cough, asthma, aspiration pneumonia, etc.


     

    Research on biomarkers has focused on identifying gastric-specific substrates found in the lungs as evidence of gastric inhalation
    .


    One of the earliest proposed biomarkers is pepsin, which is produced in the stomach.


    44%–100%

     

     

    Another potential surrogate biomarker is bile, which is found in the lungs of 38% of the adult lung transplant patients
    .


    However, it is unclear whether bile is an effective biomarker for children or non-transplant patients


    In addition, the following data are lacking in adults and children:

    (i) The relationship between the presence of gastric bile and the subsequent presence of lung bile,

    (ii) The effect of acid suppression on bile components in stomach or lung samples,

    (iii) The influence of gastric motility disorder and gastroesophageal reflux on the presence of pulmonary bile,

    (iv) The influence of lung bile on the clinical prognosis of non-transplant patients
    .

    The goal of this study is to overcome the limitations of the current literature in order to promote the understanding of bile as a potential biomarker and its related effects on the prognosis of patients with respiratory symptoms and children with lung transplantation (LTX)
    .

     

    This study prospectively recruited lung transplant (LTX) and non-transplant patients with respiratory symptoms (RP), and collected stomach and lung samples from healthy control patients
    .


    Then use liquid chromatography-mass spectrometry to evaluate the bile concentration and composition of the sample


     

     

    The researchers recruited a total of 70 patients (48 RP and 22 LTX)
    .


    Overall, 100% of stomach and 98% of bronchoalveolar lavage fluid samples contained bile


     

          This study confirms that bile is considered a marker of aspiration and a precursor to more severe lung disease in the lung transplant population
    .


    Although this study also shows that bile (especially bound bile acids) is associated with chronic lung allograft dysfunction (CLAD), it now shows that bile is also a predictor of more severe disease in non-transplant patients


      This study confirms that bile is considered a marker of aspiration and a precursor to more severe lung disease in the lung transplant population


     

    Original source:

    Rosen, Rachel.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.